Arch Therapeutics Valuation
| ARTH Stock | USD 0.21 0.01 5.00% |
Arch Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Arch Therapeutics from analyzing the firm fundamentals such as operating margin of (364.73) %, and Return On Equity of -40.15 as well as examining its technical indicators and probability of bankruptcy. . In general, most investors favor purchasing undervalued instruments and trading away overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Overvalued
Today
Please note that Arch Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Arch Therapeutics is based on 3 months time horizon. Increasing Arch Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Arch otc stock is determined by what a typical buyer is willing to pay for full or partial control of Arch Therapeutics. Since Arch Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Arch OTC Stock. However, Arch Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.21 | Real 0.2 | Hype 0.18 |
The intrinsic value of Arch Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Arch Therapeutics' stock price.
Estimating the potential upside or downside of Arch Therapeutics helps investors to forecast how Arch otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Arch Therapeutics more accurately as focusing exclusively on Arch Therapeutics' fundamentals will not take into account other important factors: Arch Therapeutics Total Value Analysis
Arch Therapeutics is presently anticipated to have valuation of 12.54 M with market capitalization of 1.44 B, debt of 2.81 M, and cash on hands of 55 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Arch Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
12.54 M | 1.44 B | 2.81 M | 55 K |
Arch Therapeutics Investor Information
About 15.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.02. Arch Therapeutics had not issued any dividends in recent years. The entity had 1:200 split on the 18th of January 2023. Based on the key indicators related to Arch Therapeutics' liquidity, profitability, solvency, and operating efficiency, Arch Therapeutics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Arch Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Arch Therapeutics has an asset utilization ratio of 0.6 percent. This signifies that the OTC Stock is making $0.006011 for each dollar of assets. An increasing asset utilization means that Arch Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Arch Therapeutics Ownership Allocation
Arch Therapeutics holds a total of 249.94 Million outstanding shares. Arch Therapeutics shows 14.58 percent of its outstanding shares held by insiders and 0.0 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Arch Therapeutics Profitability Analysis
The company reported the previous year's revenue of 15.65 K. Net Loss for the year was (5.28 M) with loss before overhead, payroll, taxes, and interest of (35.84 K).About Arch Therapeutics Valuation
An absolute valuation paradigm, as applied to Arch OTC Stock, attempts to find the value of Arch Therapeutics based on its fundamental and basic technical indicators. By analyzing Arch Therapeutics's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Arch Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Arch Therapeutics. We calculate exposure to Arch Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Arch Therapeutics's related companies.Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company was founded in 2006 and is based in Framingham, Massachusetts. Arch Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people.
8 Steps to conduct Arch Therapeutics' Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Arch Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Arch Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Arch Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Arch Therapeutics' revenue streams: Identify Arch Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Arch Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Arch Therapeutics' growth potential: Evaluate Arch Therapeutics' management, business model, and growth potential.
- Determine Arch Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Arch Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Arch Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 1.2 M | |
| Forward Price Earnings | 1.4667 | |
| Retained Earnings | -55.1 M |
Complementary Tools for Arch OTC Stock analysis
When running Arch Therapeutics' price analysis, check to measure Arch Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Therapeutics is operating at the current time. Most of Arch Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arch Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Therapeutics' price. Additionally, you may evaluate how the addition of Arch Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |